BPC-157 nasal spray: mechanism, pharmacokinetics, and the intranasal literature

BPC-157, also written as PL 14736in the early Croatian literature, is a synthetic 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protective protein isolated from human gastric juice. It has been the subject of sustained preclinical investigation by the Sikiric group at the University of Zagreb since the early 1990s, where it was originally characterized as a “body protection compound” — a short peptide that appeared to stabilize mucosal tissue against a wide range of insults.

What makes BPC-157 unusual in the research peptide landscape is its stability. Most small peptides degrade rapidly in gastric acid, plasma, or aqueous solution. BPC-157 does not. It tolerates gastric juice at pH 1 for several hours, which is part of why oral-route research has been viable where it would not be for most peptides of this length [1].

This entry summarizes the mechanistic literature on BPC-157 with a specific focus on what is and is not known about the intranasal route of administration — a route of interest to researchers because it bypasses first-pass hepatic metabolism and may provide partial access to the central nervous system via the olfactory and trigeminal pathways described by Illum [6].

The dominant mechanistic theme across the BPC-157 literature is angiogenesis. Hsieh and colleagues demonstrated that BPC-157 upregulates VEGFR2 (vascular endothelial growth factor receptor 2) and activates downstream signaling in endothelial cells, producing a pro-angiogenic phenotype without the pathological neovascularization associated with direct VEGF administration [4]. This is consistent with the earlier observation by Seiwerth et al. that BPC-157 promotes the formation of organized capillary networks in models of ischemia and wound repair [3].

A second pillar of the mechanism is interaction with the nitric oxide (NO) system. Multiple studies from the Zagreb group describe BPC-157 as rescuing both L-NAME-induced hypertension and L-arginine-overdose hypotension — effectively buffering the NO system against perturbation rather than pushing it in a single direction. This dual-directional modulation is one of the more interesting pharmacological features of the molecule and has been invoked to explain the breadth of tissue protection observed in preclinical models [1, 3].

A third, more recently characterized axis is the brain-gut connection. Sikiric and colleagues have proposed that BPC-157 influences dopaminergic, serotonergic, and GABAergic systems indirectly through its action on the gut and its vascular substrate, with measurable downstream effects on behavior in rodent models of seizure, addiction-withdrawal, and cognitive impairment [7]. This framework provides a theoretical rationale for non-gastric routes of administration, including intranasal.

Growth factor expression is also implicated: BPC-157 appears to upregulate growth hormone receptor (GHR) expression in tendon fibroblasts, which partially explains the pronounced effects observed in tendon outgrowth assays [2, 5].

The preclinical evidence base for BPC-157 is substantial but concentrated in a small number of research groups. A PubMed search as of 2026 returns several hundred entries, the majority authored or co-authored by the Sikiric group. The consistency of findings across these laboratories is a strength; the geographic concentration and the small number of independent replications outside Croatia is a limitation worth naming.

Soft tissue repair. Chang et al. (2011) showed accelerated Achilles tendon healing in rats, with improved tensile strength and histological organization at day 14 relative to controls [2]. Gwyer and colleagues subsequently reviewed the body of evidence for musculoskeletal applications and concluded that BPC-157 consistently produced positive effects in rodent tendon and ligament models across multiple independent reports [5].

Gastrointestinal. The foundational literature describes cytoprotection against NSAID-induced gastric lesions, ethanol-induced ulceration, and more severe models including short bowel syndrome and inflammatory bowel disease [1]. Mucosal healing and restoration of intestinal anastomotic strength have been reported in multiple preparations.

Neurological. The brain-gut axis review summarizes evidence in rodent models of MPTP-induced parkinsonism, haloperidol-induced catalepsy, and various ischemic and toxic insults to the CNS [7]. Effect sizes in these models are reported as substantial, but the translational distance from rodent model to human research remains large.

Human data. Published human trials are limited. A small number of early-phase safety studies have been conducted under the PL 14736 designation for ulcerative colitis. No large randomized controlled trials have been published. This is an important gap and one of the primary reasons BPC-157 remains a research compound.

Intranasal delivery of peptides has been characterized in a large body of work reviewed by Illum [6]. The practical motivation for the route is threefold: avoidance of first-pass hepatic metabolism, rapid absorption via the highly vascular respiratory epithelium, and partial access to the CNS via the olfactory and trigeminal pathways that bypass the blood-brain barrier. Reported bioavailability for small peptides via the nasal route generally falls in the 20-50% range depending on formulation, permeation enhancers, and mucociliary clearance — markedly higher than oral administration for peptides not protected by capsule or liposomal vehicle.

It is important to state plainly: the published BPC-157 literature is dominated by intraperitoneal, intragastric, and topical routes in animal models. Peer-reviewed head- to-head pharmacokinetic comparisons of intranasal BPC-157 against other routes are sparse. Researchers working with intranasal preparations should consider that the assumptions of equivalent efficacy across routes are extrapolations and not established fact.

For sourcing research-grade BPC-157 synthesized under HPLC verification with batch-matched certificates of analysis, our catalog listing is at /products/bpc-157-nasal-spray.

In research-protocol design, BPC-157 is often paired with peptides targeting orthogonal systems. The most commonly discussed pairings in the literature and in researcher protocols are:

• TB-500 (Thymosin β4 fragment) — frequently co-administered in soft-tissue repair models. The mechanisms are complementary: BPC-157 promotes angiogenesis and fibroblast migration, TB-500 is implicated in actin cytoskeletal reorganization and cell migration via a distinct pathway.
• GHK-Cu — studied in cutaneous wound models for complementary effects on collagen remodeling and copper-dependent enzymatic processes.
• Selank / Semax — when a researcher is running an intranasal protocol addressing both somatic repair and CNS-directed endpoints, the peptides are typically separated in time (different nasal sessions or different nostrils) rather than mixed in a single atomizer, to avoid unstudied formulation interactions. See our nasal stack protocols entry for separation rationale.

No formal pharmacokinetic interaction studies have been published for BPC-157 in combination with any of the above. Pairings are informed by mechanism, not by PK data.